RGLS Share Price

Open 1.05 Change Price %
High 1.10 1 Day -0.07 -6.67
Low 0.96 1 Week -0.01 -1.01
Close 0.98 1 Month -0.40 -28.99
Volume 577568 1 Year -1.89 -65.85
52 Week High 4.25
52 Week Low 0.86
RGLS Important Levels
Resistance 2 1.11
Resistance 1 1.06
Pivot 1.01
Support 1 0.90
Support 2 0.85
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
ASTI 0.00 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
QQQ 140.02 1.44%
DCTH 0.20 -9.09%
More..
NASDAQ USA Top Gainers Stocks
SPEX 1.91 70.54%
CPSL 0.09 50.00%
LOCM 0.09 50.00%
QKLS 0.15 36.36%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SPNC 38.35 26.15%
SNTA 0.34 25.93%
OTT 2.39 25.13%
THTI 0.20 17.65%
More..
NASDAQ USA Top Losers Stocks
CAFI 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Regulus Therapeutics Inc. (NASDAQ: RGLS)

RGLS Technical Analysis 5
As on 28th Jun 2017 RGLS Share Price closed @ 0.98 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.22 & Strong Sell for SHORT-TERM with Stoploss of 1.39 we also expect STOCK to react on Following IMPORTANT LEVELS.
RGLS Target for June
1st Target up-side 1.86
2nd Target up-side 2.19
3rd Target up-side 2.51
1st Target down-side 0.94
2nd Target down-side 0.61
3rd Target down-side 0.29
RGLS Other Details
Segment EQ
Market Capital 170651968.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
RGLS Address
RGLS
N/A
RGLS Latest News
Interactive Technical Analysis Chart Regulus Therapeutics Inc. ( RGLS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Regulus Therapeutics Inc.
RGLS Business Profile
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid (RNA), molecules that play a critical role in regulating key biological pathways. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs. As of December 31, 2012 , the Company�s operations included acquiring and in-licensing intellectual property rights, developing its microRNA, undertaking basic research around microRNA targets and conducting preclinical studies for its initial programs. The Company is developing RG-101 for the treatment of HCV and is advancing other microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis and metabolic diseases.